ArriVent BioPharma Target Price

Where could AVBP trade next? Consensus target price: $46.

Get informed when a big investor buys or sells

+ Follow

Share Price

$29

Average Target Price

$46.00

58.6% upside

2 analysts in the last 4 months

High: $47 | Low: $45

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-17	H.C. Wainwright	$47	62.1% upside
2026-05-29	Truist Financial	$45	55.2% upside
2025-12-10	BTIG	$45	55.2% upside
2025-11-25	Truist Financial	$43	48.3% upside
2025-07-10	Goldman SachsCorinne Johnson	$33	13.8% upside
2024-09-10	CitigroupYigal Nochomovitz	$36	24.1% upside
2024-09-10	H.C. WainwrightRobert Burns	$36	24.1% upside
2024-08-16	H.C. WainwrightRobert Burns	$30	3.4% upside
2024-07-22	OppenheimerJeff Jones	$35	20.7% upside

ArriVent BioPharma (AVBP) FAQ

The latest target price for AVBP is $46. Investors often review this figure alongside ArriVent BioPharma's historical trend and sector peers before judging valuation or financial health.

ArriVent BioPharma trades near $29.0 while the consensus target sits at $46 (58.6% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting AVBP's target price ($46), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.